Clinical Trials Directory

Trials / Completed

CompletedNCT06498557

Postoperative Analgesis in Total Knee Arthroplasty

Results of Postoperative Analgesis Protocols Applied in Total Knee Arthroplasty:Observational Study

Status
Completed
Phase
Study type
Observational
Enrollment
70 (actual)
Sponsor
Senay Canikli · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Postoperative analgesic treatment methods are applied to patients who have undergone knee arthroplasty. These applications are a routine part of the procedure. It is medically and ethically necessary. Postoperative analgesia applications are started during the intraoperative period and continued during the postoperative period. The analgesia protocol to be used is shaped by the characteristics of the patient and the skill and experience of the anesthesiologist. The scientifically accepted method is multimodel analgesia protocols. These protocols cover a wide range from paracetamol to opioids to peripheral and central blocks (methods such as suprainguinal fascia iliac block (SFIP), adductor block (ACB) and infiltration analgesia (IPACK) applied between the posterior elements of the knee and the popliteal artery). Our aim in this study is to evaluate the effects of analgesia protocols applied to patients undergoing knee arthroplasty surgery on inflammatory biomarkers (such as neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), systemic immune inflammation score (SII), lactate) obtained from routine blood and blood gas examinations in the first 24 hours of the postoperative period.

Conditions

Interventions

TypeNameDescription
OTHERPeripheral nerve block methodsWe apply different nerve blocks to patients for analgesic purposes after knee replacement surgery. These blocks are a combination of SFIP block and adductor channel block and iPACK block.

Timeline

Start date
2024-07-22
Primary completion
2024-10-04
Completion
2024-10-05
First posted
2024-07-12
Last updated
2024-11-25

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT06498557. Inclusion in this directory is not an endorsement.